Finlandja - Finlandiż - Fimea (Suomen lääkevirasto)

mylan ab - dasatinib - tabletti, kalvopäällysteinen - 100 mg - dasatinibi

Finlandja - Finlandiż - Fimea (Suomen lääkevirasto)

mylan ab - dasatinib - tabletti, kalvopäällysteinen - 140 mg - dasatinibi

Unjoni Ewropea - Finlandiż - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinibin - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiset aineet - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.

Finlandja - Finlandiż - Fimea (Suomen lääkevirasto)

stada arzneimittel ag - imatinib mesylate - tabletti, kalvopäällysteinen - 600 mg - imatinibi

Unjoni Ewropea - Finlandiż - EMA (European Medicines Agency)

actavis group ptc ehf - imatinibi - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. vaikutukset imatinibi on luuytimensiirron lopputulokseen ei ole selvitetty. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. kokemusta imatinib potilailla, joilla on mds/mpd, jotka liittyvät pdgfr-geenin uudelleenjärjestäytymisen yhteydessä järjestelyt on hyvin rajallinen. ei ole kontrolloituja tutkimuksia, jotka osoittaisivat kliinistä tehoa tai eloonjäämisetua näissä sairauksia.

Finlandja - Finlandiż - Fimea (Suomen lääkevirasto)

teva b.v. - dasatinibi monohydricum - tabletti, kalvopäällysteinen - 20 mg - dasatinibi

Finlandja - Finlandiż - Fimea (Suomen lääkevirasto)

teva b.v. - dasatinibi monohydricum - tabletti, kalvopäällysteinen - 50 mg - dasatinibi

Finlandja - Finlandiż - Fimea (Suomen lääkevirasto)

teva b.v. - dasatinibi monohydricum - tabletti, kalvopäällysteinen - 70 mg - dasatinibi

Finlandja - Finlandiż - Fimea (Suomen lääkevirasto)

teva b.v. - dasatinibi monohydricum - tabletti, kalvopäällysteinen - 80 mg - dasatinibi

Finlandja - Finlandiż - Fimea (Suomen lääkevirasto)

teva b.v. - dasatinibi monohydricum - tabletti, kalvopäällysteinen - 100 mg - dasatinibi